Exosome Diagnostics, Inc., a developer of revolutionary, biofluid-based molecular diagnostics, today announced a strategic collaboration with the Addario Lung Cancer Medical Institute (ALCMI) to accelerate the development of its lead plasma-based diagnostics in development for mutation detection and monitoring in patients with lung cancer. The collaboration will support validation of Exosome Diagnostics' ALK and T790M lab developed tests (LDTs) planned to launch in 2015 and help advance future development of the company's ALK and T790M in vitro diagnostic (IVD) kits.